Literature DB >> 19406343

The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?

Sorin J Brener.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19406343     DOI: 10.1016/j.jacc.2009.02.009

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  2 in total

1.  GPIIb/IIIa Receptor Antagonism Using Small Molecules Provides no Additive Long-Term Protection after Percutaneous Coronary Intervention as Compared to Clopidogrel Plus Aspirin.

Authors:  Michele Schiariti; Angela Saladini; Francesco Papalia; Placido Grillo; Cristina Nesta; Domenico Cuturello; Bindo Missiroli; Paolo Emilio Puddu
Journal:  Open Cardiovasc Med J       Date:  2010-07-20

Review 2.  Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives.

Authors:  Artur Dziewierz; Tomasz Rakowski; Dariusz Dudek
Journal:  Ther Clin Risk Manag       Date:  2014-07-18       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.